New insights into lipid metabolism in chronic kidney disease: What are the practical implications?

Blood Purification

Volumn 27, Issue 1, 2009, Pages 86-91

  Kaysen, George A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Fibric acid; High density lipoprotein; Inflammation; Low density lipoprotein; Remnant particles; Statins; Very low density lipoprotein

Indexed keywords

ALPHA TOCOPHEROL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; OXALIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE KIDNEY FAILURE; ANTIOXIDANT ACTIVITY; BARIATRIC SURGERY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; KINESIOTHERAPY; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; NEPHROLITHIASIS; OBESITY; PRIORITY JOURNAL; RISK REDUCTION; SODIUM INTAKE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

DYSLIPIDEMIAS; HUMANS; HYPERLIPIDEMIAS; KIDNEY DISEASES; LIPID METABOLISM;

EID: 58849144240     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167015     Document Type: Conference Paper

References (48)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
2. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-476.
3. Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004;15:538-548.
4. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-482.
5. Chertow GM, Goldstein-Fuchs DJ, Lazarus JM, Kaysen GA: Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. Kidney Int 2005;68:2794-2800.
6. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000;58:293-301.
7. Kurella M, Lo JC, Chertow GM: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-2140.
8. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association, National Heart, Lung, and Blood Institute: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-438.
9. Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, Gaziano JM: Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005;46:871-880.
10. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D: Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844-850.
11. Hocher B, Ziebig R, Altermann C, et al: Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol 2003;14:2329-2337.
12. Stompor T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Tracz W, Zdzienicka A, Klimeczek P, Janusz-Grzybowska E: An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003;41:203-211.
13. Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ: Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 2004;24:1703-1707.
14. Quintao EC, Medina WL, Passarelli M: Related reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 2000;16:237-250.
15. Mekki K, Bouchenak M, Lamri M, Remaoun M, Belleville J: Changes in plasma lecithin: cholesterol acyltransferase activity, HDL(2), HDL(3) amounts and compositions in patients with chronic renal failure after different times of hemodialysis. Atherosclerosis 2002;162:409-417.
16. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S: Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999;34:438-444.
17. Sakata K, Kashiwagi K, Sharmin S, Ueda S, Irie Y, Murotani N, Igarashi K: Increase in putrescine, amine oxidase, and acrolein in plasma of renal failure patients. Biochem Biophys Res Commun 2003;305:143-149.
18. Vaziri ND, Liang K, Parks JS: Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 2001;59:2192-2196.
19. Odamaki M, Furuya R, Ohkawa S, Yoneyama T, Nishikino M, Hishida A, Kumagai H: Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol Dial Transplant 1999;14:2427-2432.
20. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R: Relationship between plasma lipids and all-cause mortality in non-demented elderly. J Am Geriatr Soc 2005;53:219-226.
21. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297-304.
22. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.
23. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators: Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-1454.
24. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators: Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-1139.
25. Akçiçek F, Ok E, Duman S, Kürsad S, Unsal A, Alev M, Atabay G, Basçi A: Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study. Adv Perit Dial 1996;12:261-265.
26. Massy ZA, Ma JZ, Louis TA, Kasiske BL: Lipid-lowering therapy in patients with renal disease. Kidney Int 1995;48:188-198.
27. Dogra G, Irish A, Chan D, Watts G: A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007;49:776-785.
28. Nagai T, Tomizawa T, Nakajima K, Mori M: Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb 2000;7:91-96.
29. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC: Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis 2004;44:832-839.
30. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC; Veterans' Affairs High-Density Lipoprotein Intervention Trial (VAHIT) Investigators: Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004;66:1123-1130.
31. Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN: Related LDL and HDL subclass distribution in patients with endstage renal diseases. Clin Biochem 2002;35:211-216.
32. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-462.
33. Morena M, Cristol JP, Dantoine T, Carbonneau MA, Descomps B, Canaud B: Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant 2000;15:389-395.
34. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G: Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 2007;17:296-304.
35. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I: Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000;150:217-224.
36. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-160.
37. Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, Gaziano JM: Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005;46:871-880.
38. Kramer HJ, Saranathan A, Luke A, Durazo-Arvizu RA, Guichan C, Hou S, Cooper R: Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006;17:1453-1459.
39. Packard DP, Milton JE, Shuler LA, Short RA, Tuttle KR: Implications of chronic kidney disease for dietary treatment in cardiovascular disease. J Ren Nutr 2006;16:259-268.
40. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association: Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006;47:296-308.
41. Reddy ST, Wang CY, Sakhaee K, Brinkley L, Pak CY: Effect of low-carbohydrate high-protein diets on acid-base balance, stoneforming propensity, and calcium metabolism. Am J Kidney Dis 2002;40:265-274.
42. Batsis JA, Romero-Corral A, Collazo-Clavell ML, Sarr MG, Somers VK, Lopez-Jimenez F: Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc 2008;83:897-907.
43. Frige' F, Laneri M, Veronelli A, Folli F, Paganelli M, Vedani P, Marchi M, Noe' D, Ventura P, Opocher E, Pontiroli AE: Bariatric surgery in obesity: changes of glucose and lipid metabolism correlate with changes of fat mass. Nutr Metab Cardiovasc Dis 2008, E-pub ahead of print.
44. Kligman MD, Dexter DJ, Omer S, Park AE: Shrinking cardiovascular risk through bariatric surgery: application of Framingham risk score in gastric bypass. Surgery 2008;143:533-538.
45. Alexander JW, Goodman H: Gastric bypass in chronic renal failure and renal transplant. Nutr Clin Pract 2007;22:16-22.
46. Nasr SH, D'Agati VD, Said SM, Stokes MB, Largoza MV, Radhakrishnan J, Markowitz GS: Oxalate nephropathy complicating Roux-en-Y gastric bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol 2008, E-pub ahead of print.
47. Hassan I, Juncos LA, Milliner DS, Sarmiento JM, Sarr MG: Chronic renal failure secondary to oxalate nephropathy: a preventable complication after jejunoileal bypass. Mayo Clin Proc 2001;76:758-760.
48. Sharma SK, McCauley J, Cottam D, Mattar SG, Holover S, Dallal R, Lord J, Danner O, Ramanathan R, Eid G, Schauer P: Acute changes in renal function after laparoscopic gastric surgery for morbid obesity. Surg Obes Relat Dis 2006;2:389-392.